Potassium-Sparing Diuretics Market size was valued at USD 112.04 million in 2024 and is likely to cross USD 236.06 million by 2037, registering more than 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of potassium-sparing diuretics is estimated at USD 122.87 million.
The growth of the market can be attributed to the increasing prevalence of hypertension and metabolic disorders. According to WHO statistics, nearly 1.28 billion adults aged 30–79 worldwide suffer from hypertension, the majority (80%) living in low- and middle-income countries. According to the CDC, nearly half of Americans (46 percent, or 116 million) suffer from hypertension, which is defined as a systolic blood pressure over 130 mmHg or a diastolic blood pressure over 80 mmHg or are taking hypertension medications. Potassium-sparing diuretics help to reduce blood pressure by increasing the amount of potassium in the body. This helps to reduce the levels of sodium in the bloodstream, which in turn reduces the amount of fluid in the body and thus the pressure of the blood on the walls of the blood vessels.
In addition to these, factors that are believed to fuel the market growth of potassium-sparing diuretics include the increasing demand for better healthcare and innovations in the drug delivery system. Moreover, the growing number of investments in the healthcare sector and increased awareness of the availability and importance of these medications are also expected to contribute to market growth. The United States spent more than 17 percent of its GDP on healthcare in 2021. Nearly USD 28 billion was invested in the Indian healthcare sector between April 2000 and December 2021. Governments around the world are investing heavily in healthcare infrastructure and services, which is contributing to increased awareness of health and wellness, and in turn, driving the demand for potassium-sparing diuretics for a variety of ailments.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.90% |
|
Base Year Market Size (2024) |
USD 112.04 million |
|
Forecast Year Market Size (2037) |
USD 236.06 million |
|
Regional Scope |
|
Application (Edema, Hypertension, Heart Failure, Liver Cirrhosis)
The global potassium-sparing diuretics market is segmented and analyzed for demand and supply by application in edema, hypertension, heart failure, liver cirrhosis and others. Out of these, the hypertension segment is estimated to gain the largest market share of about 32% in the year 2037. The growth of the segment can be attributed to the increasing prevalence of hypertension globally owing to rising obesity and unhealthy and sedentary lifestyle habits. Approximately 60% of U.S. adults do not participate in the recommended amount of physical activity. It is estimated that 25 percent of U.S. adults are not physically active at all. Unhealthy lifestyle habits such as lack of physical activity, unhealthy dietary habits, smoking and alcohol consumption have been associated with increasing levels of obesity, which in turn increases the risk of hypertension. Additionally, increasing government initiatives for preventative healthcare and awareness about hypertension and its risk factors are also expected to contribute to the growth of this segment.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The global potassium-sparing diuretics market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies and others. Out of these, the hospital pharmacies segment is estimated to gain a significant market share of about 29% in the year 2037. The hospital pharmacies segment is expected to grow at a rapid pace owing to the increasing demand for generic drugs in hospitals, rising number of surgeries, and increasing spending capacity on healthcare in developing countries. Moreover, hospital pharmacies have access to more specialized equipment and a wider range of medications than regular pharmacies, which allows them to provide more tailored medication to their patients, resulting in a growing number of hospitals with specialty pharmacies. It was observed that more than 21% of hospitals have specialty pharmacies in 2018, up from less than 8% in 2016. Furthermore, rising investments in healthcare infrastructure and the presence of a large number of hospitals in urban and rural areas are also expected to drive the growth of the segment.
Our in-depth analysis of the global market includes the following segments:
|
By Application |
|
|
By Distribution Channel |
|
North American Market Forecast
North America industry is poised to dominate majority revenue share of 39% by 2037, The growth of the market can be attributed primarily to the increasing prevalence of cardiovascular diseases and the increasing demand for safe and effective medicines. The increasing acceptance of new technologies and the growing number of clinical trials for the development of new drugs and treatments as well as the growing investments in research and development activities by pharmaceutical and biotechnological companies, are also expected to aid in the growth of the market. A total of USD 83 billion was spent on R&D by the pharmaceutical industry in 2019 in the United States. Also, from 2010 to 2019, 59 novel drugs were approved for sale, a 60 percent increase over the previous decade. Companies are investing in research and development activities in order to develop newer and more effective potassium-sparing diuretics that can help those suffering from illnesses such as hypertension, congestive heart failure, and edema. Furthermore, the rising number of initiatives taken by governments and private organizations to create awareness about cardiovascular diagnostics and their treatments, are expected to fuel regional market growth.
APAC Market Statistics
The Asia Pacific potassium-sparing diuretics market is estimated to be the second largest, registering a share of about 25% by the end of 2036. The growth of the market can be attributed majorly to the increasing populace of geriatrics suffering from chronic kidney diseases as well as hypertension and other cardiovascular diseases. The study indicated that the overall self-reported prevalence of diagnosed CVDs was 30% for older adults aged 45 and above in India. Also, as per WHO, China's population is ageing at the fastest rate in the world. Chinese citizens over 60 are expected to reach 28% by 2040. As people age, they often develop hypertension and other conditions that require diuretics to manage water retention. Potassium-sparing diuretics are preferred for elderly individuals as they are gentler on the kidneys and help retain potassium levels, which are important for proper functioning of the heart and other organs. In addition, increasing health awareness and initiatives by governments to control the prevalence of diabetes and hypertension, and the growing focus on preventive healthcare are expected to contribute to the growth of the Asia Pacific potassium-sparing diuretics market in the near future.
Europe Market Forecast
Further, the potassium-sparing diuretics market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of this market can be attributed to the rising prevalence of lifestyle diseases such as hypertension and diabetes. A growing awareness of early diagnosis and treatment options among regional populations is expected to boost demand for potassium-sparing diuretics. As people become more aware of the early signs of kidney disease, they are more likely to seek medical attention and treatment. Potassium-sparing diuretics are becoming increasingly popular as they help to reduce the risk of developing kidney disease.
A new FDA approval for Merck & Co., Inc., VERQUVO® (vericiguat) has been announced. heart failure (HF) hospitalization risk reduction with VERQUVO in adults with symptomatic chronic heart failure and a low ejection fraction (45%) after heart failure hospitalization or need for intravenous (IV) diuretics in adults.
In a joint announcement today, Boehringer Ingelheim GmbH and Eli Lilly and Company announced that Jadix® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration for the reduction of cardiovascular death and hospitalization associated with heart failure in adults with heart failure with reduced ejection fractions (HFrEF).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?